Findings in the Area of Lung Cancer Reported from Kindai University (Analysis of Risk Factors for Febrile Neutropenia In Patients With Small-cell Lung Cancer Receiving Carboplatin Plus Etoposide Therapy).

A study conducted at Kindai University in Osaka, Japan, aimed to identify risk factors for febrile neutropenia (FN) in patients with small-cell lung cancer (SCLC) receiving carboplatin plus etoposide therapy. The study found that the co-administration of proton pump inhibitors (PPIs) or potassium-competitive acid blockers (PCABs) and a low body mass index (BMI) were significantly associated with FN. Patients with both factors had a higher frequency of FN compared to those without the factors. This research provides valuable insights into the risk factors for FN in SCLC patients undergoing this specific chemotherapy regimen. [Extracted from the article]